Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
Antonios BertsiasNestor AvgoustidisIoannis PapalopoulosArgyro RepaNikolaos KougkasEleni KalogiannakiGeorgios BertsiasIrini FlouriProdromos SidiropoulosPublished in: Arthritis research & therapy (2022)
In a cohort of patients with established RA and significant comorbidities who taper rituximab after substantial initial disease activity improvement, a low rate of relapses and lower risk of SAEs compared to SD were recorded. Seropositivity, a lower number of previous bDMARDs use, and lower DAS28 at 6 months predicted the probability of entering the LD regimen.
Keyphrases
- disease activity
- rheumatoid arthritis patients
- rheumatoid arthritis
- systemic lupus erythematosus
- diffuse large b cell lymphoma
- ankylosing spondylitis
- juvenile idiopathic arthritis
- end stage renal disease
- newly diagnosed
- hodgkin lymphoma
- chronic lymphocytic leukemia
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors